Factor XIIa inhibition by Infestin-4: In vitro mode of action and in vivo antithrombotic benefit

Thrombosis and Haemostasis

Volumn 111, Issue 4, 2013, Pages 694-704

  Xu, Yiming ^a,b   Cai, Tian Quan ^a   Castriota, Gino ^a   Zhou, Yuchen ^a   Hoos, Lizbeth ^a   Jochnowitz, Nina ^a   Loewrigkeit, Christopher ^a   Cook, John A ^a   Wickham, Alexandra ^a   Metzger, Joseph M ^a   Ogletree, Martin L ^a   Seiffert, Dietmar A ^a   Chen, Zhu ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bleeding; Coagulation; Factor XIIa; Infestin 4; Thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR 12A; INFESTIN 4; PEPTIDES AND PROTEINS; PREKALLIKREIN; UNCLASSIFIED DRUG; BLOOD CLOTTING FACTOR 10A; FIBRINOLYTIC AGENT; INFESTIN PROTEIN, TRIATOMA INFESTANS; INSECT PROTEIN; KALLIKREIN; THROMBIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTERIOVENOUS SHUNT; ARTICLE; BINDING AFFINITY; BLEEDING; BLEEDING TIME; BLOOD CLOTTING TIME; COMPETITIVE INHIBITION; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG SELECTIVITY; ENZYME ASSAY; HEMOSTASIS; HUMAN; HUMAN CELL; IC 50; MALE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; RABBIT; RAT; THROMBOSIS; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; BLOOD CLOTTING; DISEASE MODEL; DRUG EFFECTS; HEMORRHAGE; METABOLISM; SPRAGUE DAWLEY RAT;

ANIMALS; BLOOD COAGULATION; DISEASE MODELS, ANIMAL; FACTOR XA; FACTOR XIIA; FIBRINOLYTIC AGENTS; HEMORRHAGE; HEMOSTASIS; HUMANS; INSECT PROTEINS; KALLIKREINS; MALE; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; THROMBIN; THROMBOSIS;

EID: 84893856544     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH13-08-0668     Document Type: Article

References (38)

1. Davie EW, Ratnoff OD. Waterfall Sequence for Intrinsic Blood Clotting. Science 1964; 145: 1310-1312.
2. Furie B, Furie BC. The molecular basis of blood coagulation. Cell 1988; 53: 505-518.
3. Mackman N. Triggers, targets and treatments for thrombosis. Nature 2008; 451: 914-918.
4. Renne T, Gailani D. Role of Factor XII in haemostasis and thrombosis: clinical implications. Expert Rev Cardiovasc Ther 2007; 5: 733-741.
5. Renne T, Schmaier AH, Nickel KF, et al. In vivo roles of factor XII. Blood 2012; 120: 4296-4303.
6. Saito H. Contact factors in health and disease. Semin Thromb Haemost 1987; 13: 36-49.
7. Lammle B, Wuillemin WA, Huber I, et al. Thromboembolism and bleeding tendency in congenital factor XII deficiency--a study on 74 subjects from 14 Swiss families. Thromb Haemost 1991; 65: 117-121.
8. Renne T, Pozgajova M, Gruner S, et al. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med 2005; 202: 271-281.
9. Kleinschnitz C, Stoll G, Bendszus M, et al. Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischaemia without interfering with haemostasis. J Exp Med 2006; 203: 513-518.
10. Muller F, Mutch NJ, Schenk WA, et al. Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell 2009; 139: 1143-1156.
11. von Bruhl ML, Stark K, Steinhart A, et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med 2012; 209: 819-835.
12. Revenko AS, Gao D, Crosby JR, et al. Selective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombosis in mice without increased risk of bleeding. Blood 2011; 118: 5302-5311.
13. Hojima Y, Pierce JV, Pisano JJ. Hageman factor fragment inhibitor in corn seeds: purification and characterisation. Thromb Res 1980; 20: 149-162.
14. Rand MD, Lock JB, van't Veer C, et al. Blood clotting in minimally altered whole blood. Blood 1996; 88: 3432-3445.
15. Luddington R, Baglin T. Clinical measurement of thrombin generation by calibrated automated thrombography requires contact factor inhibition. J Thromb Haemost 2004; 2: 1954-1959.
16. Dargaud Y, Luddington R, Baglin TP. Elimination of contact factor activation improves measurement of platelet-dependent thrombin generation by calibrated automated thrombography at low-concentration tissue factor. J Thromb Haemost 2006; 4: 1160-1161.
17. Hojima Y, Pierce JV, Pisano JJ. Pumpkin seed inhibitor of human factor XIIa (activated Hageman factor) and bovine trypsin. Biochemistry 1982; 21: 3741-3746.
18. Baeriswyl V, Calzavarini S, Gerschheimer C, et al. Development of a Selective Peptide Macrocycle Inhibitor of Coagulation Factor XII toward the Generation of a Safe Antithrombotic Therapy. J Med Chem 2013; Epub ahead of print.
19. Robert S, Bertolla C, Masereel B, et al. Novel 3-carboxamide-coumarins as potent and selective FXIIa inhibitors. J Med Chem 2008; 51: 3077-3080.
20. Kraft P, Schwarz T, Pochet L, et al. COU254, a specific 3-carboxamide-coumarin inhibitor of coagulation factor XII, does not protect mice from acute ischaemic stroke. Exp Transl Stroke Med 2010; 2: 5.
21. Campos IT, Tanaka-Azevedo AM, Tanaka AS. Identification and characterisation of a novel factor XIIa inhibitor in the hematophagous insect, Triatoma infestans (Hemiptera: Reduviidae). FEBS Lett 2004; 577: 512-516.
22. Hagedorn I, Schmidbauer S, Pleines I, et al. Factor XIIa inhibitor recombinant human albumin Infestin-4 abolishes occlusive arterial thrombus formation without affecting bleeding. Circulation 2010; 121: 1510-1517.
23. Chen JW, Figueiredo JL, Wojtkiewicz GR, et al. Selective factor XIIa inhibition attenuates silent brain ischaemia: application of molecular imaging targeting coagulation pathway. JACC Cardiovasc Imaging 2012; 5: 1127-1138.
24. Xu Y, Wu W, Wang L, et al. Differential profiles of thrombin inhibitors (heparin, hirudin, bivalirudin, and dabigatran) in the thrombin generation assay and thromboelastography in vitro. Blood Coagul Fibrinolysis 2013; 24: 332-338.
25. Schumacher WA, Bostwick JS, Stewart AB, et al. Effect of the direct factor Xa inhibitor apixaban in rat models of thrombosis and haemostasis. J Cardiovasc Pharmacol 2010; 55: 609-616.
26. Wong PC, Quan ML, Crain EJ, et al. Nonpeptide factor Xa inhibitors: I. Studies with SF303 and SK549, a new class of potent antithrombotics. J Pharmacol Exp Ther 2000; 292: 351-357.
27. Wong PC, Crain EJ, Watson CA, et al. Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor dabigatran in rabbits. J Thromb Haemost 2009; 7: 1313-1320.
28. Pedicord DL, Seiffert D, Blat Y. Substrate-dependent modulation of the mechanism of factor XIa inhibition. Biochemistry 2004; 43: 11883-11888.
29. Luettgen JM, Knabb RM, He K, et al. Apixaban inhibition of factor Xa: Microscopic rate constants and inhibition mechanism in purified protein systems and in human plasma. J Enzyme Inhib Med Chem 2011; 26: 514-526.
30. Woodruff RS, Xu Y, Layser J, et al. Inhibiting the intrinsic pathway of coagulation with a factor XII-targeting RNA aptamer. J Thromb Haemost 2013; 11: 1364-1373.
31. Bjorkqvist J, Sala-Cunill A, Renne T. Hereditary angioedema: a bradykinin-mediated swelling disorder. Thromb Haemost 2013; 109: 368-374.
32. Wachtfogel YT, Pixley RA, Kucich U, et al. Purified plasma factor XIIa aggregates human neutrophils and causes degranulation. Blood 1986; 67: 1731-1737.
33. Konings J, Govers-Riemslag JW, Philippou H, et al. Factor XIIa regulates the structure of the fibrin clot independently of thrombin generation through direct interaction with fibrin. Blood 2011; 118: 3942-3951.
34. Yau JW, Stafford AR, Liao P, et al. Corn trypsin inhibitor coating attenuates the prothrombotic properties of catheters in vitro and in vivo. Acta Biomater 2012; 8: 4092-4100.
35. Iwaki T, Castellino FJ. Plasma levels of bradykinin are suppressed in factor XIIdeficient mice. Thromb Haemost 2006; 95: 1003-1010.
36. Bradford HN, Pixley RA, Colman RW. Human factor XII binding to the glycoprotein Ib-IX-V complex inhibits thrombin-induced platelet aggregation. J Biol Chem 2000; 275: 22756-22763.
37. Campos IT, Souza TA, Torquato RJ, et al. The Kazal-type inhibitors infestins 1 and 4 differ in specificity but are similar in three-dimensional structure. Acta Crystallogr D Biol Crystallogr 2012; 68: 695-702.
38. Weiss R, Silverberg M, Kaplan AP. The effect of C1 inhibitor upon Hageman factor autoactivation. Blood 1986; 68: 239-243.